Agreed, as I said for the preprint of this study I think the biggest take home is that the evidence is rated as low/very low quality
-
-
Replying to @GidMK @boulware_dr
I don’t think this is the same SRMA as the pre-print you are referring to is it?
1 reply 0 retweets 0 likes -
Replying to @dnunan79 @boulware_dr
Unless I'm getting very confused this study was preprinted a couple of months ago?
1 reply 0 retweets 2 likes -
Replying to @GidMK @boulware_dr
I saw your critique of another recent one from authors w notable COIs (that concluded benefit). I'm getting lost in all the reviews for this intervention. Bottom line for me = refer to high-quality BMJ rapid recs living SR (published0 or wait for Cochrane SR under peer-review
1 reply 0 retweets 1 like -
Replying to @dnunan79 @boulware_dr
Oh nah this is a different paper. I am mostly waiting for Cochrane at this point, there are just too many ivermectin reviews!
1 reply 0 retweets 2 likes -
The Bryant meta analysis has come out that was done to Chochrane methodology
1 reply 0 retweets 0 likes -
Actually according to the Cochrane team that is doing their review into ivermectin the Bryant review did not follow Cochrane methods (despite reporting that they did)
1 reply 0 retweets 3 likes -
Would be great to see the two opposing reviews face off on mainstream media
1 reply 0 retweets 0 likes -
'Opposing' - if they are answering the same question w the same evidence then should be similar findings/conclusions. I'll do an analysis of both (& a 3rd BMJ review) for decisions made & their justifications so folk can see which, if any, are being true to the data/evidence.
1 reply 0 retweets 2 likes -
Is see we will soon have a Cochrane argument over the same trials
1 reply 0 retweets 0 likes
Not really - there's a reason that Cochrane tends to be trusted, and it's because their reviews are incredibly detailed and thorough. They're usually just the best evidence out there 
-
-
Great. Let’s watch the public debate.
1 reply 0 retweets 0 likes -
One difference between the two recent meta-analyses is this current one focuses on mild, outpatient disease primarily (which is not at all obvious in the title or abstract). Separating therapeutics for outpatient mild disease vs. hospitalized severe disease is appropriate.
0 replies 0 retweets 2 likes
End of conversation
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.